Kalvista Pharmaceuticals, Inc. · NASDAQ:KALV
Kalvista Pharmaceuticals — Technical Presentation (2024)
11 slides from Kalvista Pharmaceuticals's technical presentation, 2024
Slide 1: Real-World Barriers to On-Demand Treatment for Attacks in Hereditary Angioedema: A Patient Survey
Real-World Barriers to On-Demand Treatment for Attacks in Hereditary Angioedema: A Patient Survey Daisuke Honda1, Sandra Christiansen2, Julie Ulloa3, Sherry Danese3, Vibha Desai4, Tomas Andriotti4*, Shigeru Yoshida4, Paul Audhya4, Michihiro Hide5 1Chiba University Graduate School of Medicine, Chiba,
Slide 2: Disclosures
Disclosures • Daisuke Honda has received honoraria as a speaker and advisor from KalVista, BioCryst, CSL Behring, Takeda, and Torii • This study was funded by KalVista Pharmaceuticals 2
Slide 3: Background
Background • Hereditary angioedema (HAE) is characterized by unpredictable swelling attacks that affect cutaneous and submucosal tissues and are typically painful, debilitating, and potentially fatal • WAO/EAACI 2021 updated guidelines recommend the early use of on-demand treatment following attack
Slide 4: Methods
Methods • The US Hereditary Angioedema Association recruited participants with Type 1 or 2 HAE between April and June 2023 • Participants had to be at least 12 years old and have treated at least 1 HAE attack within the prior 3 months with an approved on-demand therapy to be included in the survey •
Slide 5: Participant Characteristics (Subcutaneous subgroup)
Participant Characteristics (Subcutaneous subgroup) • 61 out of 94 (64.9%) participants who completed the survey treated their last attack with subcutaneous on-demand treatment Participants who used subcutaneous Total on-demand treatment (n=61) Current age, years; mean (SD) 46 (15.2) Gender Male 12
Slide 6: Long-Term Prophylaxis Agent Among Patients Treating with Subcutaneous On-Demand Treatment
Long-Term Prophylaxis Agent Among Patients who Treated their Last Attack with Subcutaneous On-Demand Treatment Lanadelumab 65% Plasma derived C1 esterase inhibitor (Haegarda) 24% Berotralstat 9% Plasma derived C1 esterase inhibitor (Cinryze) 3% % of Respondents (n=34) 6
Slide 7: Time to On-Demand Treatment After Initial Attack Recognition
Time to on-Demand Treatment After Initial Attack Recognition < 1 hour 26% 1 to < 2 hours 16% 2 to < 5 hours 34% 5 to < 8 hours 20% ≥ 8 hours 3% % of Respondents (n=61) • Mean reported time (standard deviation) from attack onset to on-demand treatment was 2.9 (3.6) hours 7
Slide 8: Barriers to Treating HAE Attack Sooner (Top 5 Ranked)
Barriers to Treating HAE Attack Sooner (Top 5 Ranked) • Respondents were asked to rank their top 5 reasons from a list of possible reasons for delaying the administration of on-demand treatment 4% • Reasons for not treating earlier were reported by 53/61 (87%) patients* 4% I was not certain it was a
Slide 9: Reported Level of Anxiety Associated with Use of Subcutaneous On-demand Treatment
Reported Level of Anxiety Associated with Use of Subcutaneous On-demand Treatment Extremely anxious (7-10) 28% Moderately anxious (4-6) 13% Mildly anxious (1-3) 33% Not anxious (0) 26% % of Respondents (n=61) How much anxiety did you feel about treating this HAE attack with on-demand treatment (on a
Slide 10: Reported Reasons for Feeling Anxious About Treating Most Recent Attack
Reported Reasons for Feeling Anxious About Treating Most Recent Attack with Subcutaneous On-Demand Treatment (Top 5 Ranked) Respondents (n=45)* were asked to rank their top 5 reasons from a list of possible factors contributing to their anxiety about treating their most recent attack with on-demand
Slide 11: Conclusions
Conclusions • Results suggest that many patients with HAE who are prescribed subcutaneous on- demand treatment do not follow guideline recommendations for initiating treatment as soon as an attack is recognized • Reasons for delaying treatment included uncertainty whether the attack was real, desire
KalVista Pharmaceuticals — Technical Presentation (2024) on 6ix